Source comparison
PT-141 Protocol Comparison: Dosing and Timing Variables
Starting dose 0.5mg subcutaneous 1.0mg subcutaneous 1.5mg subcutaneous Start at 1.0mg unless subject has documented MC4R sensitivity history. 0.5mg delays titration unnecessarily for most subjects Timing before observation 90 minutes 60–75 minutes 45 minutes 6
This comparison does not assign a generated winner or score.
- Starting dose
- 0.5mg subcutaneous
- 1.0mg subcutaneous
- 1.5mg subcutaneous
- Start at 1.0mg unless subject has documented MC4R sensitivity history. 0.5mg delays titration unnecessarily for most subjects
- Timing before observation
- 90 minutes
- 60–75 minutes
- 45 minutes
- 60–75 minutes aligns with peak receptor activation in 80% of subjects. Earlier timing risks subtherapeutic effect, later timing wastes protocol time
- Titration increment
- +0.25mg per protocol
- +0.5mg per protocol
- +1.0mg if no response
- +0.5mg per protocol is optimal. Allows response assessment without excessive delay while avoiding overshoot that triggers adverse events
- Nausea management
- Pre-dose with ondansetron
- Monitor and adjust dose if needed
- Continue at same dose
- Ondansetron pre-dosing removes a confounding variable. Better to titrate dose downward than add antiemetics unless nausea persists below 1.0mg
- Maximum research dose
- 1.5mg
- 2.0mg
- 2.5mg
- 2.0mg represents the ceiling dose used in Phase 3 trials. Doses above 2.0mg increase adverse events without proportional efficacy gains
- Injection site
- Abdominal subcutaneous
- Abdominal or thigh subcutaneous
- Any subcutaneous site
- Abdominal provides most consistent absorption. Thigh and arm sites show 15–20% higher variability in time-to-peak concentration